Golimumab as rescue therapy for refractory immune-mediated uveitis: A three-center experience

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Cordero Coma, Miguel ^a,b   Calvo Río, Vanesa ^c   Adán, Alfredo ^d   Blanco, Ricardo ^c   Álvarez Castro, Carolina ^a   Mesquida, Marina ^d   Calleja, Sara ^a   González Gay, Miguel A ^c   Ruíz De Morales, José G ^a,b  

^a Hospital of Leon   (Spain)

^b UNIVERSITY OF LEÓN   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CENTRAL MACULAR THICKNESS; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNE MEDIATED UVEITIS; IMMUNOSUPPRESSIVE TREATMENT; MALE; RETINA MACULA EDEMA; RETROSPECTIVE STUDY; SKIN MANIFESTATION; TERTIARY CARE CENTER; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UVEITIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS; YOUNG ADULT;

EID: 84902133795     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/717598     Document Type: Article

References (25)

1. Nussenblatt R. B., Nussenblatt R. B., Whitcup S. M., Philosophy, goals, and approaches to medical therapy. Uveitis: Fundamentals and Clinical Practice 2010 4th Mosby-Elesvier 76 113
2. Sfikakis P. P., Theodossiadis P. G., Katsiari C. G., Kaklamanis P., Markomichelakis N. N., Effect of infliximab on sight-threatening panuveitis in Behçet's disease. The Lancet 2001 358 9278 295 296 2-s2.0-0035963872 10.1016/S0140-6736(01)05497-6
3. Tugal-Tutkun I., Mudun A., Urgancioglu M., Kamali S., Kasapoglu E., Inanc M., Gül A., Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis and Rheumatism 2005 52 8 2478 2484 2-s2.0-23644447065 10.1002/art.21231
4. Díaz-Llopis M., Salom D., Garcia-De-Vicuña C., Cordero-Coma M., Ortega G., Ortego N., Suarez-De-Figueroa M., Rio-Pardo M. J., Fernandez-Cid C., Fonollosa A., Blanco R., Garcia-Aparicio A. M., Benitez-Del-Castillo J. M., Olea J. L., Arevalo J. F., Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012 119 8 1575 1581 2-s2.0-84864466773 10.1016/j.ophtha.2012.02.018
5. Arayssi T., Hamra R., Homeidan F., Uthman I., Awwad S. T., Mroue K., Mansour W., Bashshur Z. F., The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis. Clinical and Experimental Rheumatology 2005 23 3 427 2-s2.0-20444436787
6. Cordero-Coma M., Yilmaz T., Onal S., Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocular Immunology and Inflammation 2013 21 1 19 27 2-s2.0-84879518149 10.3109/09273948.2012.723107
7. Sakai T., Watanabe H., Kuroyanagi K., Akiyama G., Okano K., Kohno H., Tsuneoka H., Health- and vision-related quality of life in patients receiving infliximab therapy for Behçet uveitis. British Journal of Ophthalmology 2013 97 3 338 342 2-s2.0-84874657522 10.1136/bjophthalmol-2012-302515
8. Levy-Clarke G., Jabs D. A., Read R. W., Rosenbaum J. T., Vitale A., Van Gelder R. N., Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014 121 3 785 796 10.1016/j.ophtha.2013.09.048
9. Ash Z., Emery P., Golimumab -a new tool in the armoury against inflammatory arthritis. Annals of Medicine 2011 43 2 133 141 2-s2.0-79951575578 10.3109/07853890.2010.549148
10. Cordero-Coma M., Salom D., Díaz-Llopis M., López-Prats M. J., Calleja S., Golimumab for uveitis. Ophthalmology 2011 118 9 1892 e4 2-s2.0-80052490380 10.1016/j.ophtha.2011.05.019
11. William M., Faez S., Papaliodis G. N., Lobo A.-M., Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. Journal of Ophthalmic Inflammation and Infection 2012 2 4 231 233 2-s2.0-84869836247 10.1007/s12348-012-0081-y
12. Faez S., Lobo A. M., Sobrin L., Papaliodis G. N., Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clinical & Experimental Ophthalmology 2013 10.1111/ceo.12207
13. Nussenblatt R. B., Palestine A. G., Chan C.-C., Roberge F., Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985 92 4 467 471 2-s2.0-0021816412
14. Jabs D. A., Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. American Journal of Ophthalmology 2005 140 3 509 516 2-s2.0-24044463655 10.1016/j.ajo.2005.03.057
15. Santos Lacomba M., Marcos Martín C., Gallardo Galera J. M., Gómez Vidal M. A., Collantes Estévez E., Ramírez Chamond R., Omar M. M., Aqueous humor and serum tumor necrosis factor- α in clinical uveitis. Ophthalmic Research 2001 33 5 251 255 2-s2.0-0035741959 10.1159/000055677
16. Sakaguchi M., Sugita S., Sagawa K., Itoh K., Mochizuki M., Cytokine production by T cells infiltrating in the eye of uveitis patients. Japanese Journal of Ophthalmology 1998 42 4 262 268 2-s2.0-0032124411 10.1016/S0021-5155(98)00016-1
17. Dick A. D., Forrester J. V., Liversidge J., Cope A. P., The role of tumour necrosis factor (TNF- α) in experimental autoimmune uveoretinitis (EAU). Progress in Retinal and Eye Research 2004 23 6 617 637 2-s2.0-4544290245 10.1016/j.preteyeres.2004.06.005
18. Kump L. I., Castañeda R. A. C., Androudi S. N., Reed G. F., Foster C. S., Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology 2006 113 10 1874 1877 2-s2.0-33748956114 10.1016/j.ophtha.2006.05.016
19. Power W. J., Rodriguez A., Pedroza-Seres M., Foster C. S., Outcomes in anterior uveitis associated with the HLA-B27 haplotype. Ophthalmology 1998 105 9 1646 1651 2-s2.0-0031793309 10.1016/S0161-6420(98)99033-9
20. Durrani O. M., Tehrani N. N., Marr J. E., Moradi P., Stavrou P., Murray P. I., Degree, duration, and causes of visual loss in uveitis. British Journal of Ophthalmology 2004 88 9 1159 1162 2-s2.0-4344564392 10.1136/bjo.2003.037226
21. Lardenoye C. W. T. A., van Kooij B., Rothova A., Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006 113 8 1446 1449 2-s2.0-33746301969 10.1016/j.ophtha.2006.03.027
22. Giraudo E., Primo L., Audero E., Gerber H.-P., Koolwijk P., Soker S., Klagsbrun M., Ferrara N., Bussolino F., Tumor necrosis factor- α regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. Journal of Biological Chemistry 1998 273 34 22128 22135 2-s2.0-0032555509 10.1074/jbc.273.34.22128
23. Hangai M., He S., Hoffmann S., Lim J. I., Ryan S. J., Hinton D. R., Sequential induction of angiogenic growth factors by TNF- α in choroidal endothelial cells. Journal of Neuroimmunology 2006 171 1-2 45 56 2-s2.0-29244486471 10.1016/j.jneuroim.2005.09.018
24. Rothova A., Inflammatory cystoid macular edema. Current Opinion in Ophthalmology 2007 18 6 487 492 2-s2.0-38449109935 10.1097/ICU.0b013e3282f03d2e
25. - T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study. Eye 2012 26 3 468 477 2-s2.0-84858110063 10.1038/eye.2011.320